Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs AGEN 2034 (Primary)
- Indications Adenocarcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Agenus
- 20 Oct 2018 Results presented in an Agenus media release.
- 20 Oct 2018 According to an Agenus media release, results from this study were presented at the 2018 European Society for Medical Oncology (ESMO) Congress.
- 09 Oct 2018 According to an Agenus media release, data will be presented at the European Society for Medical Oncology (ESMO) Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History